Alvotech provides update on status of u.s. biologics license application for avt04

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the us food and drug administration (fda) has issued a complete response letter (crl) for alvotech's biologics license application (bla) for avt04, a biosimilar candidate to stelara® (ustekinumab).
ALVO Ratings Summary
ALVO Quant Ranking